• FirefoxTry Yahoo Finance on Firefox »
  •  Dow  Nasdaq
    {"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}
     Dow  Nasdaq
    {"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}

    Quote Results

    Add Quotes

    SymbolTime & PriceChg & % ChgDay's Low & HighVolumeAvg VolMkt CapChartMore Info
    Dec 2 61.13 - - - - 0 10,639,500 168.54B Sparkline Chart Chart, News, Stats, Options, Board
    No such ticker symbol: REAL-TIMETry Symbol Lookup
    {"s" : "mrk","k" : "t53,l84,c63,p43,g53,h53,v53,j10,c63,l84,p43,a00,a50,b00,b60,g00,h00,t53,v53","o" : "","j" : "c63,l84,p43,t53,v53"}

    Quotes delayed, except where indicated otherwise.

    Recent News

    day and time symbols news headline and source
    Sunday December 4, 2016
    Merck CEO Ken Frazier Is A Quote Machine at Forbes08:00am EST
    Saturday December 3, 2016
    Why Bristol-Myers Squibb Co. Stock Surged in November at Motley Fool09:43am EST
    Friday December 2, 2016
    Tech Data’s board gets more diverse with addition of former Merck executive at American City Business Journals03:05pm EST
    Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda at Insider Monkey01:17pm EST
    AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy at Market Realist11:04am EST
    Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? at Market Realist10:04am EST
    Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma Zacks09:52am EST
    Merck KGaA (MKGAF) Expands Distribution Deal with Roche Zacks08:57am EST
    Keytruda Is Merck’s Immuno-Oncology Business at Market Realist08:04am EST
    Label Expansion May Boost Venclexta’s Growth Prospects at Market Realist08:04am EST
    Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Zacks06:40am EST
    Thursday December 1, 2016
    Recent R&D Developments from Merck You Won’t Want to Miss at Market Realist11:05am EST
    What’s Forcing Valeant to Sell Its Core Assets? at Market Realist11:04am EST
    Bringing foreign drugs into the US market is a dangerous ... CNBC10:55am EST
    Alexandria Real Estate, Merck Ink Long-Term Pharma Lease Zacks10:39am EST
    AbbVie’s Plans for ABT-555, a Novel Multiple Sclerosis Therapy at Market Realist10:04am EST
    Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study Zacks09:08am EST
    Inside Merck’s Business Segment-Wise Performance at Market Realist08:05am EST
    AbbVie Is Focused on Growth Opportunities in Neuroscience Space at Market Realist08:04am EST
    Pfizer’s Profitability and Financial Guidance at Market Realist08:04am EST
    3 Ways Organovo Holdings, Inc. Plans to Grow Exponentially for Years to Come at Motley Fool07:48am EST
    Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : December 1, 2016 at Capital Cube07:39am EST